OMNISCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
OMNISCAN by GE HealthCare is 12. First approved in 2007.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMNISCAN (gadodiamide) is a paramagnetic contrast agent administered intravenously to enhance MRI visualization of normal and pathologic tissue. It works by altering local magnetic fields to decrease T1 and T2 relaxation times, increasing signal intensity in lesions such as neoplasms, abscesses, and infarcts. It is indicated for use in patients with chronic kidney disease undergoing MRI imaging.
LOE Approaching
As a product approaching loss of exclusivity, the OMNISCAN team is likely in transition mode with focus on defending market share against generics and managing declining revenue.
Mechanism of Action
12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These variations occur due to: changes in proton density; alteration of the spin-lattice or longitudinal relaxation time (T 1 );…
Worked on OMNISCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.